On the other hand, lncRNA PCA3 is specifically overexpressed in most PCa cancer patients (Bussemakers et al., 1999) and has been approved by the FDA as a PCa diagnostic marker in the urine of PCa patients (de Kok et al., 2002; Deras et al., 2008), but its use for assessing response to ADT in advanced PCa is limited (Martinez-Pineiro et al., 2014). The gene discussed is PCA3; the disease is posterior cortical atrophy.